A single month, reconciled. Every figure traces back to dispensing data, the Drug Tariff and your remittances.
A line that made money in October can turn. The dip in February is concession-driven, and recoverable.
Net cost versus what you were actually reimbursed, line by line. Click a column to sort; filter by flag.
| Item▾ | Net cost▾ | Reimbursed▾ | Margin £▾ | Flag▾ |
|---|---|---|---|---|
| Total, lines shown |
Net margin by therapeutic class. Two classes carry the practice; two are losing money.
A ranked list of what to do, with the value at stake. None of it requires changing what you prescribe.
Wholesaler rebate running ~13% against a ~25% achievable rate. The single biggest lever, a procurement conversation, not a clinical one.
Lines bought above reimbursement during shortages. About £11,100 over six months versus what the Tariff paid back.
About £19k a year of contribution that evaporates if specific price concessions are withdrawn. Worth watching and hedging.
A cheaper same-month source existed on several lines. Ordering discipline, not concessions, quick to fix.